pharma · Solid Tumors, Colorectal Cancer and Breast Cancer · HER2 Mutant Non-small Cell Lung Cancer · ELVN
Enliven Therapeutics
Enliven Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker ELVN. Primary therapeutic focus areas include Solid Tumors, Colorectal Cancer and Breast Cancer, HER2 Mutant Non
Boulder, USA HQ
2019 Founded
75 Employees
Public company Type
ELVN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2019
- Employees
- 75
- Programs
- 6
- Drugs
- 13
- Patents
- 5
ELVN-002
Phase 1 · small molecule · HER2 Mutant Non-small Cell Lung Cancer
ELVN-002 for HER2 Mutant Non-small Cell Lung Cancer is a Phase 1 program (small_molecule) at Enliven Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ELVN-002-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Enliven Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- HER2 Mutant Non-small Cell Lung Cancer
- Status
- active
- Trials
- 1